Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

2 results about "Statin" patented technology

Statins, also known as HMG-CoA reductase inhibitors, are a class of lipid-lowering medications that reduce illness and mortality in those who are at high risk of cardiovascular disease. Low-density lipoprotein (LDL) carriers of cholesterol play a key role in the development of atherosclerosis and coronary heart disease via the mechanisms described by the lipid hypothesis. Statins are effective in lowering LDL cholesterol and so are widely used for primary prevention in people at high risk of cardiovascular disease, as well as in secondary prevention for those who have developed cardiovascular disease.

Pharmaceutical composition for promoting bone healing after osteoportic fracture operations and application of pharmaceutical composition

InactiveCN104587470ALower doseSmall toxicitySkeletal disorderEster active ingredientsLovastatinStatine
The invention discloses a pharmaceutical composition for promoting bone healing after osteoportic fracture operations and application of the pharmaceutical composition. The pharmaceutical composition comprises statins and ketorolac tromethamine, wherein the statins are selected from one or more of simvastatin, lovastatin and atorvastatin. The pharmaceutical composition has the advantages of improving the bone mass of osteoporosis patients to a greater extent and accelerating the healing of osteoportic fracture to improve the mechanical property.
Owner:THE FIRST AFFILIATED HOSPITAL OF XINXIANG MEDICAL UNIV

Improved process for preparing a statin precursor

InactiveUS20180111906A1Increase productionOrganic chemistryOrganic solventMethyl group
The present invention relates to a process comprising reacting p-fluorobenzaldehyde, 4-methyl-3-oxopentanenitrile and urea in a first reaction mixture comprising a first organic solvent, thereby obtaining an intermediate mixture comprising an oxo-pyrimidine-carbonitrile; and oxidizing the oxo-pyrimidine-carbonitrile by contacting the intermediate mixture or organic extract with an organic hydroperoxide, thereby obtaining a hydroxyl-pyrimidine carbonitrile.
Owner:DSM SINOCHEM PHARMA NETHERLANDS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products